Covid19-Sources

Täglich veröffentlichen wir an dieser Stelle um 13.00 Uhr die aktuellen Daten des DIVI-Intensivregisterszu den derzeitigen intensivmedizinischen Behandlungskapazitäten in Deutschland. Das Register wurde im Frühjahr 2020 gemeinsam mit dem RKI aufgebaut. Deshalb verfügen wir erst...

+++Aktualisierung (Stand: 20.07.2020)+++ Aktivierung des Kinder-Intensivregisters am 20.07.20, 14 Uhr

Auch im Sommer infizieren sich immer mehr Kinder mit RSV. Die Niederlande verzeichnen derzeit einen starken Anstieg an Infektionen. Muss Deutschland sich jetzt bereit machen?

Während bei den mRNA-Vakzinen von Biontech und Moderna nur Risikogruppen eine Auffrischung empfohlen wird, gilt dies für die Vektor-Impfstoffe von Astrazeneca und Johnson&Johnson grundsätzlich. Warum ist das so? Müssen sich Impflinge Sorgen machen?

28 June 2021

The Oxford-AstraZeneca COVID-19 vaccine ChAdOx1 nCoV-19 is associated with a risk for vaccine-induced immune thrombosis with thrombocytopenia syndrome in the range of one to two cases per 100 000 vaccinations, with younger women showing the highest risk.1,2 Additional cases have been reported for the Johnson & Johnson adenoviral vector-based Ad26.CoV2.S COVID-19 vaccine.3 Vaccine-induced antibodies against platelet factor 4 have been implicated in the pathogenesis.1,2 These antibodies might be amplified by booster vaccination with an adenoviral vector, which prompted recommendations to boost with an mRNA-based vaccine instead, although data on safety and efficacy of heterologous prime–boost regimens are sparse.

Although COVID-19 in children is usually of short duration with low symptom burden, some children with COVID-19 experience prolonged illness duration. Reassuringly, symptom burden in these children did not increase with time, and most recovered by day 56. Some children who tested negative for SARS-CoV-2 also had persistent and burdensome illness. A holistic approach for all children with persistent illness during the pandemic is appropriate.

@f2135 Literatur zB https://t.co/VyrAamAxrT https://t.co/LfY16PYkdS https://t.co/NsdWsNv70c

A heroic community effort at a daring hospital saved lives, led to today’s ventilators and revolutionized medicine — it holds lessons for our times.

Eine neue Auswertung von AOK-Daten zeigt, dass in Deutschland wesentlich mehr COVID-Patienten mit ECMO-Beatmung versterben als anderswo. Sind wir schlechter? Oder was ist los?

As eradication of SARS-CoV-2 will be unlikely, we have high confidence in stating that there will always be variants. The number of variants will depend on control measures. We describe hypothetical scenarios by which SARS-CoV-2 could further evolve and acquire, through mutation, phenotypes of concern, which we assess according to possibility. For this purpose, we consider mutations in the ‘body’ of the virus (the viral genes that are expressed in infected cells and control replication and cell response), that might affect virus fitness and disease severity, separately from mutations in the spike glycoprotein that might affect virus transmission and antibody escape. We assess which scenarios are the most likely and what impact they might have and consider how these scenarios might be mitigated. We provide supporting information based on the evolution of SARS-CoV-2, human and animal coronaviruses as well as drawing parallels with other viruses.

A problematic statementIn an interview on May 11th 2021, Dr. Monica Gandhi said:Children and young adults are very low risk for severe disease, about one in a million chance of death for a child u

SARS-CoV-2 Lambda, a new variant of interest, is now spreading in some South American countries; however, its virological features and evolutionary trait remain unknown. Here we reveal that the spike protein of the Lambda variant is more infectious and it is attributed to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino-acid deletion mutation in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies. Since the Lambda variant has dominantly spread according to the increasing frequency of the isolates harboring the RSYLTPGD246-253N mutation, our data suggest that the insertion of the RSYLTPGD246-253N mutation is closely associated with the massive infection spread of the Lambda variant in South America. Highlights ![Figure][1] ### Competing Interest Statement The authors have declared no competing interest. [1]: pending:yes

Ein Göttinger Forscherteam hat Mini-Antikörper entwickelt, die das Coronavirus SARS-CoV-2 und dessen gefährliche neue Varianten effizient ausschalten. Die sogenannten Nanobodies binden und neutralisieren das Virus bis zu 1000 Mal besser als zuvor entwickelte Mini-Antikörper. Zudem konnten die Wissenschaftler*innen die Mini-Antikörper so weit perfektionieren, dass sie sehr stabil sind und extreme Hitze unbeschadet überstehen. Diese einzigartige Kombination macht sie zu einem vielversprechenden Wirkstoff, um COVID-19 zu behandeln. Da sich Nanobodies kostengünstig und schnell in großen Mengen herstellen lassen, könnten sie sogar den weltweiten Bedarf an COVID-19-Medikamenten decken. Sie werden aktuell für klinische Tests vorbereitet. (The EMBO Journal, 24. Juli 2021) +++ Gemeinsame Presseinformation von Max-Planck-Institut für biophysikalische Chemie, Göttingen, und Universitätsmedizin Göttingen +++

Rather disappointed by the reporting of what is a heavily flawed study in the media to suggest that long COVID is rare in children. There are many issues with this study that I'm sure long COVID researchers & patients will flag, but here's my analysis🧵 https://t.co/IVPGwWBsFr

Our study is the first to demonstrate the presence of the COVID-19 virus in the penis long after the initial infection in humans. Our results also suggest that widespread endothelial cell dysfunction from COVID-19 infection can contribute to ED. Future studies will evaluate novel molecular mechanism …

Background: The emergency use authorization for coronavirus disease 2019 (COVID-19) vaccines brought both hopes and concerns to the Americans and others. We aimed to estimate the mortality rate of COVID-19 vaccination and presented characteristics of deaths following COVID-19 vaccination. …

Scientific Reports - <ArticleTitle Language="En" OutputMedium="All" xml:lang="en">Rates of SARS-CoV-2 transmission and...

Objectives Highly effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed but variants of concerns (VOCs) with mutations in the spike protein are worrisome, especially B.1.617.2 (Delta) which has rapidly spread across the world. We aim to study if vaccination alters virological and serological kinetics in breakthrough infections. Methods We conducted a multi-centre retrospective cohort study of patients in Singapore who had received a licensed mRNA vaccine and been admitted to hospital with B.1.617.2 SARS-CoV-2 infection. We compared the clinical features, virological and serological kinetics (anti-nucleocapsid, anti-spike and surrogate virus neutralization titres) between fully vaccinated and unvaccinated individuals. Results Of 218 individuals with B.1.617.2 infection, 84 had received a mRNA vaccine of which 71 were fully vaccinated, 130 were unvaccinated and 4 received a non-mRNA. Despite significantly older age in the vaccine breakthrough group, the odds of severe COVID-19 requiring oxygen supplementation was significantly lower following vaccination (adjusted odds ratio 0.07 95%CI: 0.015-0.335, p=0.001). PCR cycle threshold (Ct) values were similar between both vaccinated and unvaccinated groups at diagnosis, but viral loads decreased faster in vaccinated individuals. Early, robust boosting of anti-spike protein antibodies was observed in vaccinated patients, however, these titers were significantly lower against B.1.617.2 as compared with the wildtype vaccine strain. Conclusion The mRNA vaccines are highly effective at preventing symptomatic and severe COVID-19 associated with B.1.617.2 infection. Vaccination is associated with faster decline in viral RNA load and a robust serological response. Vaccination remains a key strategy for control of COVID-19 pandemic. ### Competing Interest Statement BEY reports personal fees from Roche and Sanofi, outside the submitted work. All other authors declare no competing interests. ### Funding Statement This study was funded by grants from the Singapore National Medical Research Council (COVID19RF-001, COVID19RF-008). The funders had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Written informed consent was obtained from study participants of the multi-centre study approved by National Healthcare Group Domain Specific Review Board (NHG-DSRB) (Study Reference 2012/00917). Informed consent for retrospective data collection at National Centre for Infectious Diseases (NCID) was waived (NHG-DSRB reference number 2020/01122). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

I've been talking about ivermectin a bit recently, and every time I mention it someone will link me to this odd website - ivmmeta dot comSo, a bit of a review. I think this falls pretty solidly into the category of pseudoscience 1/n pic.twitter.com/JPVUIeKOcs— Health Nerd (@GidMK) August 2, 2021

Daten der AOK und Barmer zeigen: Müssen COVID-19-Patienten beatmet werden, liegen die Fallkosten im fünfstelligen Bereich. Dabei ist noch unklar, welche gesundheitlichen Folgeschäden auftreten.

Assuming further that 30 and 50% of individuals were immune to Spanish influenza after the wave in April 1918 and the first subsequent wave, respectively, these findings imply that, in a totally susceptible population, an infectious case could have led to 2.4-4.3 and 2.6-10.6 cases in community-base …

Why children are generally less susceptible than adults to COVID-19 is unclear and has not extensively been examined longitudinally. Here the authors compare antibodies, cytokines and immune cell...

Die Uniklinik Essen forscht an einem neuen Corona-Medikament. Wenn alles glattläuft, könnte es schon bald auf den Markt kommen. Doch es stehen noch Tests an.

In December 2019, a pneumonia-like disease caused an outbreak in the city of Wuhan, China1. This disease, later named COVID-19, spread globally and was declared a pandemic in March 2020 by the World Health Organisation. By April 2021 it has already affected around 145 million people and resulted in more than three million deaths globally2. Until effective treatments are available and vaccines are extensively accessible and administered, governments rely on non-pharmaceutical interventions (NPIs) to control the epidemic.

New CDC data go against a pervasive narrative.

Original Article from The New England Journal of Medicine — Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Vaccines that are sprayed into the nose could induce mucosal immunity and help stop the spread of the coronavirus, if vaccine developers can prove that they work

Places and activities during which infection prevention and control measures may be difficult to fully enforce were those with increased risk of infection. Children attending day-care, kindergarten, middle and high schools, but not primary schools, were potential sources of infection for the household.